These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 7729950)
1. Resistance-associated factors in human small-cell lung-carcinoma GLC4 sub-lines with increasing adriamycin resistance. Versantvoort CH; Withoff S; Broxterman HJ; Kuiper CM; Scheper RJ; Mulder NH; de Vries EG Int J Cancer; 1995 May; 61(3):375-80. PubMed ID: 7729950 [TBL] [Abstract][Full Text] [Related]
2. An etoposide-resistant lung cancer subline overexpresses the multidrug resistance-associated protein. Doyle LA; Ross DD; Ordonez JV; Yang W; Gao Y; Tong Y; Belani CP; Gutheil JC Br J Cancer; 1995 Sep; 72(3):535-42. PubMed ID: 7669558 [TBL] [Abstract][Full Text] [Related]
3. Multifactorial involvement of multidrug resistance-associated [correction of resistance] protein, DNA topoisomerase II and glutathione/glutathione-S-transferase in nonP-glycoprotein-mediated multidrug resistance in human bladder cancer cells. Kim WJ; Kakehi Y; Yoshida O Int J Urol; 1997 Nov; 4(6):583-90. PubMed ID: 9477189 [TBL] [Abstract][Full Text] [Related]
4. Differential expression of DNA topoisomerase II alpha and -beta in P-gp and MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines of the human SCLC cell line GLC4. Withoff S; de Vries EG; Keith WN; Nienhuis EF; van der Graaf WT; Uges DR; Mulder NH Br J Cancer; 1996 Dec; 74(12):1869-76. PubMed ID: 8980384 [TBL] [Abstract][Full Text] [Related]
5. Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line. de Jong S; Zijlstra JG; de Vries EG; Mulder NH Cancer Res; 1990 Jan; 50(2):304-9. PubMed ID: 1967222 [TBL] [Abstract][Full Text] [Related]
6. Altered MRP is associated with multidrug resistance and reduced drug accumulation in human SW-1573 cells. Eijdems EW; Zaman GJ; de Haas M; Versantvoort CH; Flens MJ; Scheper RJ; Kamst E; Borst P; Baas F Br J Cancer; 1995 Aug; 72(2):298-306. PubMed ID: 7640209 [TBL] [Abstract][Full Text] [Related]
7. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833. Beketic-Oreskovic L; DurĂ¡n GE; Chen KG; Dumontet C; Sikic BI J Natl Cancer Inst; 1995 Nov; 87(21):1593-602. PubMed ID: 7563202 [TBL] [Abstract][Full Text] [Related]
8. Characterisation of multidrug-resistant Ehrlich ascites tumour cells selected in vivo for resistance to etoposide. Nielsen D; Maare C; Eriksen J; Litman T; Friche E; Skovsgaard T Biochem Pharmacol; 2000 Aug; 60(3):353-61. PubMed ID: 10856430 [TBL] [Abstract][Full Text] [Related]
9. Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines. Hasegawa S; Abe T; Naito S; Kotoh S; Kumazawa J; Hipfner DR; Deeley RG; Cole SP; Kuwano M Br J Cancer; 1995 May; 71(5):907-13. PubMed ID: 7734314 [TBL] [Abstract][Full Text] [Related]
10. Non-P-glycoprotein-mediated atypical multidrug resistance in a human bladder cancer cell line. Naito S; Hasegawa S; Yokomizo A; Koga H; Kotoh S; Kuwano M; Kumazawa J Jpn J Cancer Res; 1995 Nov; 86(11):1112-8. PubMed ID: 8567404 [TBL] [Abstract][Full Text] [Related]
11. Non-P-glycoprotein-mediated multidrug-resistant human KB cells selected in medium containing adriamycin, cepharanthine, and mezerein. Sumizawa T; Chuman Y; Sakamoto H; Iemura K; Almquist KC; Deeley RG; Cole SP; Akiyama S Somat Cell Mol Genet; 1994 Sep; 20(5):423-35. PubMed ID: 7825064 [TBL] [Abstract][Full Text] [Related]
13. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells. de Jong S; Kooistra AJ; de Vries EG; Mulder NH; Zijlstra JG Cancer Res; 1993 Mar; 53(5):1064-71. PubMed ID: 8382551 [TBL] [Abstract][Full Text] [Related]
14. Expression of drug resistance genes in VP-16 and mAMSA-selected human carcinoma cells. Matsumoto Y; Takano H; Kunishio K; Nagao S; Fojo T Jpn J Cancer Res; 2001 Jul; 92(7):778-84. PubMed ID: 11473729 [TBL] [Abstract][Full Text] [Related]
16. Selection of non-P-glycoprotein mediated high-level etoposide resistant cell lines by adriamycin with P-gp inhibitors. Ades S; Maxfield LF; Gould CJ; Jones GK; Levy SB Int J Oncol; 2006 Mar; 28(3):747-53. PubMed ID: 16465381 [TBL] [Abstract][Full Text] [Related]
17. Increased rate of adenosine triphosphate-dependent etoposide (VP-16) efflux in a murine leukemia cell line overexpressing the multidrug resistance-associated protein (MRP) gene. Lorico A; Rappa G; Srimatkandada S; Catapano CV; Fernandes DJ; Germino JF; Sartorelli AC Cancer Res; 1995 Oct; 55(19):4352-60. PubMed ID: 7671247 [TBL] [Abstract][Full Text] [Related]
18. Multidrug resistance-associated protein (MRP) gene expression in human lung cancer. Narasaki F; Matsuo I; Ikuno N; Fukuda M; Soda H; Oka M Anticancer Res; 1996; 16(4A):2079-82. PubMed ID: 8712746 [TBL] [Abstract][Full Text] [Related]
19. Reduced activity of topoisomerase II in an Adriamycin-resistant human stomach-adenocarcinoma cell line. Son YS; Suh JM; Ahn SH; Kim JC; Yi JY; Hur KC; Hong WS; Muller MT; Chung IK Cancer Chemother Pharmacol; 1998; 41(5):353-60. PubMed ID: 9523730 [TBL] [Abstract][Full Text] [Related]
20. Protein kinase C isoenzymes, p53, accumulation of rhodamine 123, glutathione-S-transferase, topoisomerase II and MRP in multidrug resistant cell lines. Utz I; Gekeler V; Ise W; Beck J; Spitaler M; Grunicke H; Hofmann J Anticancer Res; 1996; 16(1):289-96. PubMed ID: 8615623 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]